Table 1.
Baseline demographic and clinical characteristics of the participants.
| Characteristic | Total (N = 193) | Active group (N = 101) | Control group (N = 92) | p-Value |
|---|---|---|---|---|
| Male sex – n.(%) | 117 (61%) | 59 (50.4%) | 58 (49.6%) | >0.05 |
| Age, median (IQR) – years | 68 (47−72) | 59 (47−60) | 65 (47−77) | <0.05 |
| BMI, median (IQR) – kg/m2 | 28.3 (32.4−25.9) | 29 (26−33) | 28 (25−31) | >0.05 |
| Current smoker – n. (%) | 12 (6%) | 9 (9%) | 3 (3%) | >0.05 |
| Hypertension – n. (%) | 100 (51.8%) | 54 (54%) | 46 (50%) | >0.05 |
| Diabetes mellitus – n. (%) | 57 (29.5%) | 22 (21.8%) | 35 (38.0%) | >0.05 |
| Heart disease – n. (%) | 30 (15.5%) | 13 (12.9%) | 17 (18.5%) | >0.05 |
| Pulmonary disease – n. (%) | 13 (6.7%) | 6 (5.9%) | 7 (7.6%) | >0.05 |
| Oncologic disease – n. (%) | 10 (5.2%) | 5 (4.9%) | 5 (5.4%) | >0.05 |
| Previous use of ACEI/ARB – n. (%) | 80 (41.5%) | 45 (44.5%) | 35 (38.0%) | >0.05 |
| Previous use of statin – n. (%) | 38 (19.7%) | 16 (15.8%) | 22 (23.9%) | >0.05 |
| Previous use of metformin – n. (%) | 32 (16.6%) | 14 (13.8%) | 17 (18.5%) | >0.05 |
| qSOFA = 0 | 159 (82.4%) | 80 (79.0%) | 79 (85.9%) | >0.05 |
| qSOFA = 1 | 34 (17.6%) | 21 (21.0%) | 13 (14.1%) | |
| qSOFA = 2 | 0 | 0 | 0 | |
| qSOFA = 3 | 0 | 0 | 0 |
Abbreviations: IQR, interquartile range; BMI, body mass index; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CT, computed tomography.